Golden age of prostate cancer drug discovery and development as NICE draft guidance recommends new prostate cancer drug
Golden age of prostate cancer drug discovery and development as NICE draft guidance recommends new prostate cancer drug
22/10/2013
Responding to new NICE draft guidance recommending enzalutamide as an option for treating hormone relapsed metastatic prostate cancer in adults:
Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, London, said:
“Advanced prostate cancer is very difficult to treat, and it’s taken a coordinated effort to finally bring new drugs into the pipeline, after decades where there were no options once old-style hormone treatment stopped working.
“What we’re seeing now is an unprecedented period of success for prostate cancer research, with four new drugs shown to extend life in major clinical trials in just two years, and several others showing promise. It truly is a golden age for prostate cancer drug discovery and development.”
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden Hospital and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
Source: eCancer News: http://ecancer.org/news/4638-golden-age-of-prostate-cancer-drug-discovery-and-development-as-nice-draft-guidance-recommends-new-prostate-cancer-drug.php